REG-Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
Genmab presented post-hoc subgroup data from the pivotal Phase 3 EPCORE FL-1 trial at the 2026 EHA Congress, showing consistent efficacy for epcoritamab plus rituximab and lenalidomide in relapsed/refractory follicular lymphoma. Progression-free survival hazard ratios remained below 0.3 across all risk subgroups, including high-risk FLIPI 3-5 patients (HR 0.25) and those with early progression (POD24, HR 0.22).
Key figures
- Drug Name
- epcoritamab
- Phase Of Trial
- Phase 3
- Trial name
- EPCORE FL-1
- Pfs hr pod24
- 0.22
- Total patients
- 481
- Pfs hr flipi 0 2
- 0.18
- Pfs hr flipi 3 5
- 0.25
- Control arm patients
- 238
- Crr flipi 0 2 control
- 62.1%
- Crr flipi 3 5 control
- 35.4%
- Orr flipi 0 2 control
- 84.8%
- Orr flipi 3 5 control
- 72.6%
- Treatment arm patients
- 243
- Crr flipi 0 2 treatment
- 86.6%
- Crr flipi 3 5 treatment
- 77.0%
- Orr flipi 0 2 treatment
- 96.5%
- Orr flipi 3 5 treatment
- 93.0%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.